FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475052631> ?p ?o ?g. }

• W2475052631 abstract "Background Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review. Objectives To determine whether the use of dornase alfa in cystic fibrosis is associated with improved mortality and morbidity compared to placebo or other medications that improve airway clearance, and to identify any adverse events associated with its use. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and abstracts from conferences. Date of the most recent search of the Group's Cystic Fibrosis Register: 30 November 2015. Clinicaltrials.gov was also searched to identify unpublished or ongoing trials. Date of most recent search: 28 November 2015. Selection criteria All randomised and quasi‐randomised controlled trials comparing dornase alfa to placebo, standard therapy or other medications that improve airway clearance. Data collection and analysis Authors independently assessed trials against the inclusion criteria; two authors carried out analysis of methodological quality and data extraction. Main results The searches identified 54 trials, of which 19 (including a total of 2565 participants) met our inclusion criteria. Three additional papers examined the healthcare cost from one of the clinical trials. Fifteen trials compared dornase alfa to placebo or no dornase alfa treatment (2447 participants); two compared daily dornase to hypertonic saline (32 participants); one compared daily dornase alfa with hypertonic saline and alternate day dornase alfa (48 participants); one compared dornase alfa to mannitol and the combination of both drugs (38 participants). Trial duration varied from six days to three years. Compared to placebo, forced expiratory volume at one second improved in the intervention groups, with significant differences at one, three, six months and two years. There was also a significant improvement in lung clearance index at one month. There was a decrease in pulmonary exacerbations compared to placebo in trials of longer duration. The quality of the evidence from placebo‐controlled trials was moderate to high for outcomes of lung function and pulmonary exacerbations. Limited, low quality evidence was available for changes in quality of life from baseline. One trial that examined the cost of care, including the cost of dornase alfa, found that the cost savings from dornase alfa offset 18% to 38% of the medication costs. The results for trials comparing dornase alfa to other medications that improve airway clearance (hypertonic saline or mannitol) were mixed, with one trial showing a greater improvement in forced expiratory volume at one second for dornase alfa compared to hypertonic saline, and three trials finding no difference between medications. In the only trial to assess the combination of dornase alfa with another medication compared to dornase alone, there was no benefit seen with the combination of dornase alfa and mannitol. Evidence of dornase alfa compared to other medications was limited and the open‐label design of the trials may have induced bias, therefore the quality of the evidence was judged to be low. Dornase alfa did not cause significantly more adverse effects, except voice alteration and rash. Authors' conclusions There is evidence to show that, compared with placebo, therapy with dornase alfa improves lung function in people with cystic fibrosis in trials lasting one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to hyperosmolar agents in improving lung function." @default.
• W2475052631 created "2016-07-22" @default.
• W2475052631 creator A5004822836 @default.
• W2475052631 creator A5004868297 @default.
• W2475052631 creator A5071474299 @default.
• W2475052631 creator A5079108186 @default.
• W2475052631 date "2016-04-04" @default.
• W2475052631 modified "2023-10-09" @default.
• W2475052631 title "Dornase alfa for cystic fibrosis" @default.
• W2475052631 cites W175998601 @default.
• W2475052631 cites W177063975 @default.
• W2475052631 cites W1872952081 @default.
• W2475052631 cites W1965385540 @default.
• W2475052631 cites W1968152866 @default.
• W2475052631 cites W1970431627 @default.
• W2475052631 cites W1975609078 @default.
• W2475052631 cites W1975820788 @default.
• W2475052631 cites W1976264709 @default.
• W2475052631 cites W1976867283 @default.
• W2475052631 cites W1978271506 @default.
• W2475052631 cites W1982251574 @default.
• W2475052631 cites W1983495472 @default.
• W2475052631 cites W1991045784 @default.
• W2475052631 cites W1997567908 @default.
• W2475052631 cites W2006292526 @default.
• W2475052631 cites W2006752980 @default.
• W2475052631 cites W2010678373 @default.
• W2475052631 cites W2023546954 @default.
• W2475052631 cites W2023586232 @default.
• W2475052631 cites W2031789064 @default.
• W2475052631 cites W2036001221 @default.
• W2475052631 cites W2039548615 @default.
• W2475052631 cites W2041807185 @default.
• W2475052631 cites W2045572299 @default.
• W2475052631 cites W2046446743 @default.
• W2475052631 cites W2051130956 @default.
• W2475052631 cites W2054626218 @default.
• W2475052631 cites W2056935354 @default.
• W2475052631 cites W2057510647 @default.
• W2475052631 cites W2059734063 @default.
• W2475052631 cites W2061434168 @default.
• W2475052631 cites W2064024196 @default.
• W2475052631 cites W2070419306 @default.
• W2475052631 cites W2096869184 @default.
• W2475052631 cites W2107884278 @default.
• W2475052631 cites W2110528741 @default.
• W2475052631 cites W2112485011 @default.
• W2475052631 cites W2113032181 @default.
• W2475052631 cites W2117530267 @default.
• W2475052631 cites W2118540215 @default.
• W2475052631 cites W2119260499 @default.
• W2475052631 cites W2124135806 @default.
• W2475052631 cites W2125364344 @default.
• W2475052631 cites W2125435699 @default.
• W2475052631 cites W2127136998 @default.
• W2475052631 cites W2128817585 @default.
• W2475052631 cites W2129637598 @default.
• W2475052631 cites W2129756193 @default.
• W2475052631 cites W2129772791 @default.
• W2475052631 cites W2130235475 @default.
• W2475052631 cites W2132665778 @default.
• W2475052631 cites W2133673354 @default.
• W2475052631 cites W2136652636 @default.
• W2475052631 cites W2144145895 @default.
• W2475052631 cites W2145410540 @default.
• W2475052631 cites W2148217897 @default.
• W2475052631 cites W2150399236 @default.
• W2475052631 cites W2153943794 @default.
• W2475052631 cites W2158898740 @default.
• W2475052631 cites W2161154125 @default.
• W2475052631 cites W2165031309 @default.
• W2475052631 cites W2166747774 @default.
• W2475052631 cites W2172138333 @default.
• W2475052631 cites W2333398204 @default.
• W2475052631 cites W2336714143 @default.
• W2475052631 cites W4211009199 @default.
• W2475052631 cites W4366305930 @default.
• W2475052631 doi "https://doi.org/10.1002/14651858.cd001127.pub3" @default.
• W2475052631 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8094421" @default.
• W2475052631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33735508" @default.
• W2475052631 hasPublicationYear "2016" @default.
• W2475052631 type Work @default.
• W2475052631 sameAs 2475052631 @default.
• W2475052631 citedByCount "95" @default.
• W2475052631 countsByYear W24750526312014 @default.
• W2475052631 countsByYear W24750526312016 @default.
• W2475052631 countsByYear W24750526312017 @default.
• W2475052631 countsByYear W24750526312018 @default.
• W2475052631 countsByYear W24750526312019 @default.
• W2475052631 countsByYear W24750526312020 @default.
• W2475052631 countsByYear W24750526312021 @default.
• W2475052631 countsByYear W24750526312022 @default.
• W2475052631 countsByYear W24750526312023 @default.
• W2475052631 crossrefType "journal-article" @default.
• W2475052631 hasAuthorship W2475052631A5004822836 @default.
• W2475052631 hasAuthorship W2475052631A5004868297 @default.
• W2475052631 hasAuthorship W2475052631A5071474299 @default.
• W2475052631 hasAuthorship W2475052631A5079108186 @default.
• W2475052631 hasConcept C126322002 @default.
• W2475052631 hasConcept C142724271 @default.

• next